GSK3A and acute myeloid leukemia: In order to validate the predicted AML sensitivity to tivantinib, we treated HL60 and U937 AML cell lines with (−)-tivantinib, which is currently in advanced clinical development, its enantiomer (+)-tivantinib, which is a much weaker GSK3 inhibitor, the bona fide pan-GSK3α/β inhibitor LiCl and the MET inhibitor PF-04217903 as indicated.